Orlistat for the prevention of cardiovascular diseases in overweight or obese individuals

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Nkansah, Nancy ^a   Garala, M ^b   Agness, C ^b   Davis, B ^b   Ikediobi, O ^b   Bero, L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DYSLIPIDEMIA; FLATULENCE; GLUCOSE INTOLERANCE; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; MORBIDITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PREVALENCE; REVIEW; RISK ASSESSMENT; SLEEP APNEA SYNDROME; STEATORRHEA; STROKE; VOMITING;

EID: 44949233797     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006692     Document Type: Review

References (40)

1. Alberti 1998 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Medicine Jul 1998;15(7):539-53.
2. Borovicka 2000 Borovicka J, Schwizer W, Guttmann G, Hartmann D, Kosinski M, Wastiel C, Bischof-Delaloye A, Fried M. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor. Gut 2000;46(6):774-81.
3. Chua 1994 Chua W, Chediak, AS. Obstructive sleep apnea. Treatment improves quality of life and may prevent death. Postgraduate Medicine 1994; 95:123-38.
4. Cicuttini 1996 Cicuttini FM, Baker JR, Spector TD. The association of obesity with osteoarthritis of the hand in known women. Rhuematology 1996;23: 1221-6.
5. Cohen 1960 Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
6. Davidson 1999 Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. Journal of the American Medical Association 1999;281(3):235-42.
7. Flegal 2002 Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. Journal of the American Medical Association Oct 2002;288(14):1723-7.
8. Hauptman 1992 Hauptman, J. B. Jeunet, F. S. HaHauptman J, Jeunet J, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). American Journal of Clinical Nutrition 1992;55(1):309S-313.
9. Hedley 2004 Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. Journal of the American Medical Association 2004;291(23):2847-50.
10. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. British Medical Journal 2003;327:557-60.
11. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
12. Hollander 1998 Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21(8):1288-94.
13. Hu 2001 Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. New England Journal of Medicine 2001;345(11):790-7.
14. Kannel 2002 Kannel WB, Wilson PW, Nam BH, D'Agostino RB. Risk stratification of obesity as a coronary risk factor. The American Journal of Cardiology 2002;90(7):697-701.
15. Lakka 2002 Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men. Journal of the American Medical Association 2002;288(21):2709-16.
16. Lau 2006 Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597-600.
17. Li 2007 Li C, Ford ES, McGuire LC, Mokdad AH. Increasing Trends in Waist Circumference and Abdominal Obesity among U.S. Adults. Obesity 2007;15(1):216-224.
18. Luque 1999 Luque CA, Rey JA Luque CA, Rey JA. Sibutramine: a serotonin-nore-pinephrine reuptake-inhibitor for the treatment of obesity Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Annals of Pharmacotherapy 1999;33: 968-78. Annals of Pharmacotherapy 1999;33(9):968-78.
19. Maggio 2003 Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinology and Metabolic Clinics of North America 2003;32(4): 805-22.
20. Muls 2001 Muls E, Kolanowski J, Scheen A, Van Gaal L, ObelHyx Study Group. The effects of orlistat on weight and on serumlipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. International Journal of Obesity and Related Metabolic Disorders 2001;25(11):1713-21.
21. NIH 1993 National Institute of Health. NIH Technology Assessment Conference Panel. Methods for voluntary weight loss and control. Annals of Internal Medicine. Annals of Internal Medicine 1993;119:764-70.
22. NIH 2001 National Institutes of Health. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary National Institutes of Health. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary [Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Thir Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summary]. NIH publication number 01-3670. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute, 2001.
23. NIHCD 1985 NIHCD. National Institutes of Health Consensus Development Conference Statement (NIHCD). Health Implications of Obesity. Annals of Internal Medicine. 1985.
24. Norman 2003 JE Norman, D Bild, CE Lewis, K Liu, D Smith West. The impact of weight change on cardiovascular disease risk factors in young black and white adults: the CARDIA study. International Journal of Obesity 2003;27:369-76.
25. Norris 2004 Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, Lau J. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Archives of Internal Medicine 2004; 164(13):1395-404.
26. Ogden 2002 Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. Journal of the American Medical Association Oct 2002;288(14):1772- 3.
27. Ohlson 1985 Ohlson LO. The influence of body fat distributoi on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985;34:1055.
28. Padawal 2003 Padawal R, Li S, Lau D. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. International Journal of Obesity and Related Metabolic Disorders 2003;27(12):1437-46.
29. Pi-Sunyer 2002 Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obesity Research Dec 2002; 10(Supplement 2): 97S-104S..
30. Pi-Sunyer X 1996 Pi-Sunyer X. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clinical Therapeutics 1996;18(6):1006-1035.
31. Reaven 2001 Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. American Journal of Cardiology April 1, 2001;87(7):827-31.
32. Rexrode 1997 Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, Speizer FE, Manson JE. A prospective study of body mass index, weight change, and risk of strok in women. Journal of the American Medical Association 1997;277:1539-45.
33. Rossner 2000 Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obesity Research 2000;8(1):49-61.
34. Sjostrom 1998 Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352(9173):167-72.
35. Swinburn 2005 Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, Strauss BJ, Sullivan D, Welborn TA, Caterson ID. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes, Obesity, and Metabolism 2005;7(3):254-62.
36. Tonstad 1994 Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA, Golay A, Reitsma J, Del Bufalo A, Pasotti E, Van der Waal P. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. European Journal of Clinical Pharmacology 1994;46(5):405-10.
37. Truesdale 2007 Truesdale KP, Stevens J, Cai J. Nine-Year Changes in Cardiovascular Disease Risk Factors with Weight Maintenance in the Atherosclerosis Risk in Communities Cohort. American Journal of Epidemiology 2007;Advance access publication:1-11.
38. WHO 2000 World Health Organization. Obesity: preventing and managing the global epidemic. Techincal Report Series 894, Genevea. 2000.
39. Zavoral 1998 Zavoral J. Reduction in cardiovascular risk factors after 1 year's treatment with orlistat. American Journal of Hypertension 1998;11(4 (Supplement 1)):19A.
40. Zhi 1994 Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers.Clinical Pharmacology Therapeutics 1994;56(1):82-5.